Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Raloxifene: handle with care

Kathleen I. Pritchard, Mark Levine and Barbara Walley
CMAJ July 24, 2001 165 (2) 151-153;
Kathleen I. Pritchard
Head Division of Clinical Trials and Epidemiology Toronto-Sunnybrook Regional Cancer Centre Toronto, Ont.; Professor Department of Medicine McMaster University Hamilton, Ont.; Medical oncologist Saskatoon Cancer Centre Saskatoon, Sask. on behalf of the Ad Hoc Raloxifene in Breast Cancer Group Members of the Ad Hoc Raloxifene in Breast Cancer Group: Dr. Hasmin Alam Zeenat, Dr. Margot Burnell, Martin Blackstein, Dr. Bruce Colwell, Dr. Susan Dent, Dr. Karen Gelmon, Dr. Paul Goss, Dr. Kara Laing, Dr. Mark Levine, Dr. Lavina Lickley, Dr. Kathleen Pritchard, Dr. Andre Robidoux, Dr. Ted Vandenberg, Dr. Shaill Verma, Dr. Barbara Walley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Levine
Head Division of Clinical Trials and Epidemiology Toronto-Sunnybrook Regional Cancer Centre Toronto, Ont.; Professor Department of Medicine McMaster University Hamilton, Ont.; Medical oncologist Saskatoon Cancer Centre Saskatoon, Sask. on behalf of the Ad Hoc Raloxifene in Breast Cancer Group Members of the Ad Hoc Raloxifene in Breast Cancer Group: Dr. Hasmin Alam Zeenat, Dr. Margot Burnell, Martin Blackstein, Dr. Bruce Colwell, Dr. Susan Dent, Dr. Karen Gelmon, Dr. Paul Goss, Dr. Kara Laing, Dr. Mark Levine, Dr. Lavina Lickley, Dr. Kathleen Pritchard, Dr. Andre Robidoux, Dr. Ted Vandenberg, Dr. Shaill Verma, Dr. Barbara Walley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Walley
Head Division of Clinical Trials and Epidemiology Toronto-Sunnybrook Regional Cancer Centre Toronto, Ont.; Professor Department of Medicine McMaster University Hamilton, Ont.; Medical oncologist Saskatoon Cancer Centre Saskatoon, Sask. on behalf of the Ad Hoc Raloxifene in Breast Cancer Group Members of the Ad Hoc Raloxifene in Breast Cancer Group: Dr. Hasmin Alam Zeenat, Dr. Margot Burnell, Martin Blackstein, Dr. Bruce Colwell, Dr. Susan Dent, Dr. Karen Gelmon, Dr. Paul Goss, Dr. Kara Laing, Dr. Mark Levine, Dr. Lavina Lickley, Dr. Kathleen Pritchard, Dr. Andre Robidoux, Dr. Ted Vandenberg, Dr. Shaill Verma, Dr. Barbara Walley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

We have seen some women at high risk for breast cancer taking the selective estrogen receptor modulator raloxifene, in the belief that it is a breast cancer “preventive” with few of the risks or side effects of tamoxifen. Raloxifene is, in fact, not approved in North America for breast cancer prevention. Furthermore, perhaps because raloxifene has become available more recently, women, and sometimes physicians, do not seem to be aware that the risks of developing deep venous thrombosis, pulmonary emboli and hot flashes are similar to those seen with tamoxifen.1

We have also observed the frequent use of raloxifene by women who have completed the recommended 5-year course of adjuvant therapy with tamoxifen following a diagnosis of breast cancer. In randomized trials, there were more recurrences of breast cancer and more deaths in women who received adjuvant therapy with tamoxifen for 10 or more years than in those who received tamoxifen for 5 years.2 This may be explained by the observation in animal and in vitro models that cells grown for long periods in the presence of tamoxifen can become dependent on it.3

Because raloxifene is very similar to tamoxifen, the prescription of raloxifene to a patient with residual tamoxifen- dependent breast cancer cells could promote the growth of such a cancer. In fact, it has recently been demonstrated in animal models that tamoxifen- dependent breast cancer cells can be stimulated by raloxifene.4 Thus, physicians should be particularly concerned about the prescription of raloxifene in this situation.

If patients can develop tamoxifen- dependent breast cancers after protracted periods of therapy, perhaps women with a previous diagnosis of breast cancer who have not been treated with tamoxifen but who are treated with raloxifene for osteoporosis may develop raloxifene-dependent tumours. There are few safety data on the use of raloxifene in women with a previous diagnosis of breast cancer.5,6

In summary, raloxifene is not currently indicated for breast cancer prevention; it should not be prescribed as a substitute for tamoxifen as adjuvant therapy for breast cancer; it should not be prescribed to women who have completed 5 years of tamoxifen as adjuvant therapy for breast cancer; and the prescription of raloxifene to prevent or treat osteoporosis in women with a previous history of breast cancer who have not received tamoxifen or who have received it for less than 5 years should be considered only with caution and after discussion with the patient's medical oncologist. Alternative approaches to treat or prevent osteoporosis in women with a previous diagnosis of breast cancer include therapy with bisphosphonates, calcitonin and calcium supplements, diet modifications and exercise.

References

  1. 1.↵
    Grossman LD. Raloxifene: a review. J Soc Obstet Gynaecol Can 2000;22:183-90.
    OpenUrl
  2. 2.↵
    Fisher B, Dignan J, Bryant J. Five versus more than five years of tamoxifen for lymph node negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomised trial. J Natl Cancer Inst 2001;93:684-90.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    O'Regan RM, Gajdos C, Dardes R, de los Reyes A, Bentrem DJ, Jordan VC. Effect of raloxifene after tamoxifen on breast and endometrial cancer growth [abstract]. In: Proceedings of the 37th ASCO Annual Meeting; 2001 May 12–15; San Francisco. Abstr. no. 95.
  5. 5.↵
    Gradishar WJ, Glusman JE, Vogel CL. Raloxifene HCL, a new endocrine agent is active in estrogen receptor positive (ER+) metastatic breast cancer [abstract]. Breast Cancer Res Treat 1997;46:53. Abstr. no. 209.
    OpenUrl
  6. 6.↵
    Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344-5.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 2
24 Jul 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Raloxifene: handle with care
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Raloxifene: handle with care
Kathleen I. Pritchard, Mark Levine, Barbara Walley
CMAJ Jul 2001, 165 (2) 151-153;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Raloxifene: handle with care
Kathleen I. Pritchard, Mark Levine, Barbara Walley
CMAJ Jul 2001, 165 (2) 151-153;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
  • Raloxifene and breast cancer
  • Google Scholar

More in this TOC Section

  • A call to reconsider the new diagnostic criteria for gestational diabetes mellitus
  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire